These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33608672)

  • 1. Autophagy inhibitors increase the susceptibility of KRAS-mutant human colorectal cancer cells to a combined treatment of 2-deoxy-D-glucose and lovastatin.
    Huang XM; Huang JJ; Du JJ; Zhang N; Long Z; Yang Y; Zhong FF; Zheng BW; Shen YF; Huang Z; Qin X; Chen JH; Lin QY; Lin WJ; Ma WZ
    Acta Pharmacol Sin; 2021 Nov; 42(11):1875-1887. PubMed ID: 33608672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
    Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
    Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
    Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
    [No Abstract]   [Full Text] [Related]  

  • 5. Fangchinoline exerts anticancer effects on colorectal cancer by inducing autophagy via regulation AMPK/mTOR/ULK1 pathway.
    Xiang X; Tian Y; Hu J; Xiong R; Bautista M; Deng L; Yue Q; Li Y; Kuang W; Li J; Liu K; Yu C; Feng G
    Biochem Pharmacol; 2021 Apr; 186():114475. PubMed ID: 33609560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autophagy inhibition enhances photocytotoxicity of Photosan-II in human colorectal cancer cells.
    Xiong L; Liu Z; Ouyang G; Lin L; Huang H; Kang H; Chen W; Miao X; Wen Y
    Oncotarget; 2017 Jan; 8(4):6419-6432. PubMed ID: 28031534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel hypoxia-inducible factor-1α inhibitor IDF-11774 regulates cancer metabolism, thereby suppressing tumor growth.
    Ban HS; Kim BK; Lee H; Kim HM; Harmalkar D; Nam M; Park SK; Lee K; Park JT; Kim I; Lee K; Hwang GS; Won M
    Cell Death Dis; 2017 Jun; 8(6):e2843. PubMed ID: 28569777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations.
    Jia YT; Yang DH; Zhao Z; Bi XH; Han WH; Feng B; Zhi J; Gu B; Duan Z; Wu JH; Ju YC; Wang MX; Li ZX
    Curr Cancer Drug Targets; 2018; 18(3):278-286. PubMed ID: 28359236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel PI3K/Akt/mTOR signaling inhibitor, W922, prevents colorectal cancer growth via the regulation of autophagy.
    Wang J; Liang D; Zhang XP; He CF; Cao L; Zhang SQ; Xiao X; Li SJ; Cao YX
    Int J Oncol; 2021 Jan; 58(1):70-82. PubMed ID: 33367926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors.
    Stalnecker CA; Grover KR; Edwards AC; Coleman MF; Yang R; DeLiberty JM; Papke B; Goodwin CM; Pierobon M; Petricoin EF; Gautam P; Wennerberg K; Cox AD; Der CJ; Hursting SD; Bryant KL
    Cancer Res; 2022 Feb; 82(4):586-598. PubMed ID: 34921013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
    Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer.
    Ye H; Liu Y; Wu K; Luo H; Cui L
    Cell Commun Signal; 2020 Jul; 18(1):115. PubMed ID: 32703218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic anti-tumour effects of tetrandrine and chloroquine combination therapy in human cancer: a potential antagonistic role for p21.
    Mei L; Chen Y; Wang Z; Wang J; Wan J; Yu C; Liu X; Li W
    Br J Pharmacol; 2015 May; 172(9):2232-45. PubMed ID: 25521075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
    Goulielmaki M; Koustas E; Moysidou E; Vlassi M; Sasazuki T; Shirasawa S; Zografos G; Oikonomou E; Pintzas A
    Oncotarget; 2016 Feb; 7(8):9188-221. PubMed ID: 26802026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.
    Ziemke EK; Dosch JS; Maust JD; Shettigar A; Sen A; Welling TH; Hardiman KM; Sebolt-Leopold JS
    Clin Cancer Res; 2016 Jan; 22(2):405-14. PubMed ID: 26369631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SKF-96365 activates cytoprotective autophagy to delay apoptosis in colorectal cancer cells through inhibition of the calcium/CaMKIIγ/AKT-mediated pathway.
    Jing Z; Sui X; Yao J; Xie J; Jiang L; Zhou Y; Pan H; Han W
    Cancer Lett; 2016 Mar; 372(2):226-38. PubMed ID: 26803057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.
    Morelli MP; Tentler JJ; Kulikowski GN; Tan AC; Bradshaw-Pierce EL; Pitts TM; Brown AM; Nallapareddy S; Arcaroli JJ; Serkova NJ; Hidalgo M; Ciardiello F; Eckhardt SG
    Clin Cancer Res; 2012 Feb; 18(4):1051-62. PubMed ID: 22173548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-deoxy-D-glucose augments photodynamic therapy induced mitochondrial caspase-independent apoptosis and energy-mediated autophagy.
    Feng X; Shi Y; Xie L; Zhang K; Wang X; Liu Q; Wang P
    Lasers Surg Med; 2019 Apr; 51(4):352-362. PubMed ID: 30277589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer.
    Feng J; Jiang W; Liu Y; Huang W; Hu K; Li K; Chen J; Ma C; Sun Z; Pang X
    Biochem Pharmacol; 2020 Jul; 177():113960. PubMed ID: 32298693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.